242 552

Cited 25 times in

Verification of Current Risk Scores for Kawasaki Disease in Korean Children

DC Field Value Language
dc.contributor.author은영민-
dc.date.accessioned2018-07-20T11:57:21Z-
dc.date.available2018-07-20T11:57:21Z-
dc.date.issued2017-
dc.identifier.issn1011-8934-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161545-
dc.description.abstractThe purpose of this study was to evaluate and assess the compatibility of current risk scoring systems from Japan that were developed to predict intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD). The authors previously investigated another prediction model for patients with refractory KD in Korea. A retrospective study involving 350 patients with KD who were admitted between January 2014 and December 2015 was performed. Patients younger than 2 years were excluded for the propensity score matching in this study. Patients were classified into IVIG responders and IVIG resistance groups. The well-known Harada, Kobayashi, and Egami risk scores were calculated for each patient, and the proportion of high-risk patients was compared between the two groups for each risk score. Logistic regression analysis revealed that platelets, C-reactive protein (CRP) levels, and aspartate aminotransferase levels were independent predictors of IVIG resistance. Multivariate analysis suggested that platelets and CRP were risk factors. Risk-scoring systems from Japan have good specificity but low sensitivity. Among the three risk scoring systems, the Kobayashi risk score demonstrated significant differences between the IVIG resistance and IVIG responder groups in Korean patients with KD. It is very important to identify IVIG-resistant patients to protect them from ongoing coronary arterial lesion(s); therefore, early prediction and timely optimal additional treatment is of significant benefit. It would be helpful to construct a highly sensitive, exclusive scoring system for Korean patients with KD.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisher대한의학회(The Korean Academy of Medical Sciences)-
dc.relation.isPartOfJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAge Factors-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHAspartate Aminotransferases/blood-
dc.subject.MESHBlood Platelets/cytology-
dc.subject.MESHC-Reactive Protein/analysis-
dc.subject.MESHChild, Preschool-
dc.subject.MESHDrug Resistance-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunoglobulins, Intravenous/therapeutic use-
dc.subject.MESHInfant-
dc.subject.MESHMale-
dc.subject.MESHMucocutaneous Lymph Node Syndrome/diagnosis*-
dc.subject.MESHMucocutaneous Lymph Node Syndrome/drug therapy-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHSex Factors-
dc.titleVerification of Current Risk Scores for Kawasaki Disease in Korean Children-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pediatrics-
dc.contributor.googleauthorJaeeun Shin, Heeyoung Lee, and Lucy Eun-
dc.identifier.doi10.3346/jkms.2017.32.12.1991-
dc.contributor.localIdA02634-
dc.relation.journalcodeJ01517-
dc.identifier.eissn1598-6357-
dc.identifier.pmid29115081-
dc.subject.keywordIntravenous Immunoglobulin-
dc.subject.keywordKawasaki Disease-
dc.subject.keywordPrediction-
dc.subject.keywordResistance-
dc.subject.keywordRisk Score-
dc.contributor.alternativeNameEun, Young Min-
dc.contributor.affiliatedAuthorEun, Young Min-
dc.citation.volume32-
dc.citation.number12-
dc.citation.startPage1991-
dc.citation.endPage1996-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN MEDICAL SCIENCE, Vol.32(12) : 1991-1996, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.